KRS 194A.800: Pilot program -- Community pharmacy care for medication -assisted

substance abuse therapy -- Components -- Report.

(1) For the purposes of this section, "pilot program" means a program in a county or set

of counties, or a subset or subsets of t he population, as designated by the Cabinet

for Health and Family Services and the Department for Behavioral Health,

Developmental and Intellectual Disabilities.

(2) A pilot program is established to analyze the outcomes and effectiveness of a

community ph armacy care delivery model for medication -assisted therapy for

treatment of substance abuse in order to ensure that the Commonwealth is:

(a) Using approaches that have been shown to be effective;

(b) Intervening early at important stages and transitions; and

(c) Intervening in appropriate settings and domains.

(3) Sources of data for the pilot program shall include, at a minimum, claims data from

the Department for Medicaid Services, including claims data from Medicaid

managed care organizations submitted to the Department for Medicaid Services.

(4) As funds are available, the Cabinet for Health and Family Services shall initiate a

pilot program to determine, collect, and analyze performance measurement data for

a community pharmacy care delivery model for n oncontrolled medication-assisted

therapy as part of substance abuse treatment services to determine practices that

increase access to treatment, reduce frequency of relapse, provide better outcomes

for patients, and control health costs related to substanc e abuse treatment. Program

components shall:

(a) Use a community pharmacy care delivery model for noncontrolled

medication-assisted therapy for the treatment of substance abuse, as

authorized by the Kentucky Board of Pharmacy pursuant to KRS 315.010(25);

(b) Include a wraparound services model that engages psychological and social

support for the patient;

(c) Establish collaborative relationships between detention facilities, drug courts,

community pharmacists, and practitioners who provide psychosocial

interventions to evaluate individuals' eligibility for participation in a

community pharmacy care delivery model for noncontrolled medication -

assisted therapy; and

(d) Include pilot program data collection designed to inform the outcomes and

effectiveness of a community pharmacy care delivery model for medication -

assisted therapy for treatment of substance abuse.

(5) By December 31, 2019, the Cabinet for Health and Family Services shall provide a

joint report to the Legislative Research Commission and the Off ice of the Governor

that:

(a) Details the findings of the pilot program; and

(b) Includes recommendations based on the pilot program's results for optimizing

substance abuse treatment services provided in community pharmacies.